Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells

The Prostate
Hassan A Al SalehKhalid Al-Nedawi

Abstract

Prostate cancer (PC) patients in advanced stages of the disease have high risk of blood coagulation complications. The procoagulant molecule Tissue factor (TF), and the fibrinolysis inhibitor plasminogen activator inhibitor-1 PAI-1 play important role in this complication. Extracellular vesicles (EV) shed from cancer cells may contribute to the regulation of TF and PAI-1. The procoagulant activity of EV can be associated with the oncogenic and metastatic characteristics of their cells. We have expressed EGFRvIII in DU145 cells to assess the role of this oncogene in the procoagulant activity of EV. The intercellular exchange of TF via EV was assessed by downregulating its expression in DU145 cells using shRNA vector, and determining the transfer of TF via EV enriched with the protein. Two PC cell lines with different metastatic potential were used to assess the correlation between the procoagulant activity of EV and the metastatic potential of PC cells. Photometric assays were used to determine FXa-activity and thrombin generation as indicators for the procoagulant activity of EV. Double-tagged proteinase-activated receptor 1(PAR-1) expressed in CHO cells to assess its activation by EV. The expression of EGFRvIII in DU145 cells ...Continue Reading

References

Jan 19, 2000·British Journal of Cancer·E O Olapade-OlaopaF K Habib
Feb 15, 2001·Pathology Oncology Research : POR·M F LoretoL Ginaldi
Apr 6, 2005·Journal of the American College of Cardiology·Björn SzotowskiUrsula Rauch
May 28, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Khalid Al-NedawiCzeslaw S Cierniewski
Jul 30, 2005·Journal of Cellular Biochemistry·Kwanchanit TantivejkulKenneth J Pienta
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joanne EdwardsJohn M S Bartlett
Feb 10, 2006·Blood Cells, Molecules & Diseases·Nigel Mackman
Oct 10, 2006·Journal of General Internal Medicine·Ignacio Duran, Ian F Tannock
Feb 1, 2008·Current Oncology·K M J Brose, A Y Y Lee
Feb 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Khalid Al-NedawiJanusz Rak
Apr 18, 2009·Anesthesia and Analgesia·Kenichi A TanakaJerrold H Levy
Dec 17, 2009·Seminars in Thrombosis and Hemostasis·Giuseppe LippiEmmanuel J Favaloro
Mar 10, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Jennifer A CaldwellRichard C Austin
Feb 3, 2011·Nature Communications·Leonora BalajJohan Skog
Oct 6, 2011·Hämostaseologie·A Falanga, L Russo
Mar 20, 2012·Thrombosis Research·Romaric Lacroix, Françoise Dignat-George
Feb 20, 2013·The Journal of Cell Biology·Graça Raposo, Willem Stoorvogel
Dec 3, 2013·Thrombosis Research·Damien GheldofChristian Chatelain
Nov 26, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jolene ReadKhalid Al-Nedawi
Oct 27, 2017·The Journal of Biological Chemistry·Ali A Al-HashimiRichard C Austin

❮ Previous
Next ❯

Citations

Jan 19, 2019·Cancers·Caroline J ReddelVivien M Chen
Jul 22, 2020·Journal of Thrombosis and Haemostasis : JTH·Jan K RudzinskiPaul Jurasz
Nov 24, 2020·Hypertension·Olga Martinez-ArroyoRaquel Cortes
Aug 19, 2018·The Journal of Thoracic and Cardiovascular Surgery·Victor A Ferraris
Mar 21, 2021·Thrombosis and Haemostasis·Jun WanMark Roest

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.